HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy
- PMID: 27070123
- PMCID: PMC5106226
- DOI: 10.1097/QAI.0000000000001019
HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy
Abstract
Objective: Combination antiretroviral therapy (ART) decreases the risk of sexual HIV transmission by suppressing blood and genital HIV RNA concentrations. We sought to determine HIV transmission risk prior to achieving complete viral suppression.
Design: Prospective cohort study.
Methods: Using data from the Partners PrEP Study, a prospective study of 4747 heterosexual HIV-serodiscordant couples in Kenya and Uganda, we examined multiple markers of HIV transmission risk during the first months after ART initiation: time to viral suppression in blood, persistence of HIV RNA in genital specimens, sexual risk behavior, pregnancy incidence, and HIV transmission using survival analysis and generalized estimating equations logistic regression.
Results: The cumulative probabilities of achieving blood viral suppression (<80 copies per milliliter) 3, 6, and 9 months after ART initiation were 65.3%, 84.8%, and 89.1%, respectively. Endocervical and seminal HIV RNA were detectable in 12% and 21% of samples obtained within 6 months of ART. Pregnancy incidence was 8.8 per 100 person-years during the first 6 months of ART, and sex unprotected by condoms was reported at 10.5% of visits. Among initially uninfected partners, HIV incidence before ART was 2.08 per 100 person-years (55 infections; 2644 person-years), 1.79 for 0-6 months after ART initiation (3 infections; 168 person-years), and 0.00 with >6 months of ART (0 infections; 167 person-years).
Conclusions: Residual HIV transmission risk persists during the first 6 months of ART, with incomplete viral suppression in blood and genital compartments. For HIV-serodiscordant couples in which the infected partner starts ART, other prevention options are needed, such as pre-exposure prophylaxis, until viral suppression is achieved.
Conflict of interest statement
The authors report no conflicts of interest.
Figures
Similar articles
-
Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships.AIDS Res Hum Retroviruses. 2016 Feb;32(2):148-54. doi: 10.1089/AID.2015.0296. AIDS Res Hum Retroviruses. 2016. PMID: 26670218 Free PMC article.
-
Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis.Lancet HIV. 2017 Mar;4(3):e122-e133. doi: 10.1016/S2352-3018(16)30220-X. Epub 2016 Dec 16. Lancet HIV. 2017. PMID: 27989576 Free PMC article.
-
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.PLoS Med. 2016 Aug 23;13(8):e1002099. doi: 10.1371/journal.pmed.1002099. eCollection 2016 Aug. PLoS Med. 2016. PMID: 27552090 Free PMC article.
-
Does antiretroviral therapy prevent HIV transmission to sexual partners?Curr HIV/AIDS Rep. 2007 May;4(2):80-5. doi: 10.1007/s11904-007-0012-y. Curr HIV/AIDS Rep. 2007. PMID: 17547829 Review.
-
Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy.PLoS One. 2013;8(2):e55747. doi: 10.1371/journal.pone.0055747. Epub 2013 Feb 13. PLoS One. 2013. PMID: 23418455 Free PMC article. Review.
Cited by
-
Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology.Pharmaceuticals (Basel). 2024 Jul 4;17(7):887. doi: 10.3390/ph17070887. Pharmaceuticals (Basel). 2024. PMID: 39065738 Free PMC article. Review.
-
Effectiveness of Frequent Viral Load Testing Plus Additional Interventions to Prevent HIV Transmission in Heterosexual, Serodiscordant Couples - Yunnan Province, China, 2019-2021.China CDC Wkly. 2024 Jul 5;6(27):658-664. doi: 10.46234/ccdcw2024.122. China CDC Wkly. 2024. PMID: 39027632 Free PMC article.
-
Quantifying the impact of cascade inequalities: a modelling study on the prevention impacts of antiretroviral therapy scale-up in Eswatini.medRxiv [Preprint]. 2024 May 13:2024.02.16.24302584. doi: 10.1101/2024.02.16.24302584. medRxiv. 2024. PMID: 38405846 Free PMC article. Preprint.
-
Impact of the COVID-19 pandemic on routine HIV care and antiretroviral treatment outcomes in Kenya: A nationally representative analysis.PLoS One. 2023 Nov 27;18(11):e0291479. doi: 10.1371/journal.pone.0291479. eCollection 2023. PLoS One. 2023. PMID: 38011132 Free PMC article.
-
Trends in Time Spent Viremic Among Persons Newly Diagnosed With HIV in San Francisco.J Acquir Immune Defic Syndr. 2023 Oct 1;94(2):107-115. doi: 10.1097/QAI.0000000000003237. Epub 2023 Sep 11. J Acquir Immune Defic Syndr. 2023. PMID: 37707298 Free PMC article.
References
-
- Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921–929. - PubMed
-
- Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-infected compartments during combination therapy. Nature. 1997;387(6629):188–191. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous